Research programme: cancer immunotherapies - Minerva Biotechnologies

Drug Profile

Research programme: cancer immunotherapies - Minerva Biotechnologies

Alternative Names: CAR T therapeutics - Minerva; huMNC2-scFv-CAR T cells; MUC1*-targeting CAR T cells

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Minerva Biotechnologies
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 May 2017 Minerva Biotechnologies plans clinical trials for Breast cancer and Ovarian cancer in 2017 (Minerva Biotechnologies website, July 2016)
  • 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 12 Jul 2016 Preclinical trials in Solid tumours in USA (unspecified route) (Minerva Biotechnologies website, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top